Transfusion efficacy was influenced by gender, donor age, irradiation, apheresis collection, storage duration, and Rh-D positivity.
Isolated MYC gene rearrangement had minimal negative prognostic impact compared with double- or triple-hit lymphoma.
In patients with disease progression after first androgen-deprivation therapy, survival was longer with cabazitaxel than with abiraterone or enzalutamide.
Patients with class 3 BRAF mutations might benefit from anti-EGFR therapy; those with class 2 mutations are unlikely to respond.
Survival was superior in patients with microsatellite instability versus microsatellite stability.
A correction to a summary published September 18, 2019
Overall survival was significantly worse for men with breast cancer than for their women counterparts.
High overall response rates were noted in high-risk patients with prior hydroxyurea resistance or intolerance.
PBRT successfully spared cardiac and lung tissues while delivering a homogenous dose to the target tissue.
Early resumption of anticoagulation is essential to reduce the risk for vascular events and death.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.